RecruitingNot applicableNCT06462352
Multicenter Study Comparing AI-Based Navicam vs. Conventional Pillcam in Small Bowel Pathology
Studying NLRP3-associated autoinflammatory disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hospital Clinic of Barcelona
- Principal Investigator
- Begoña González Suárez, PhDHospital Clinic of Barcelona
- Intervention
- Navicam SB capsule(device)
- Enrollment
- 147 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2025
Study locations (16)
- Hospital General Universitario Dr Balmis, Alicante, Spain
- Hospital Clínic de Barcelona, Barcelona, Spain
- Hospital del Mar, Barcelona, Spain
- Institut de Recerca Sant Pau (IR-Sant Pau), Barcelona, Spain
- Hospital Universitario de Galdakao, Bilbao, Spain
- Hospital General Universitario Virgen la Arrixaca, El Palmar, Spain
- Hospital General Universitario de Elche, Elche, Spain
- Hospital Clínico San Carlos, Madrid, Spain
- Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Hospital General Universitario Morales Meseguer, Murcia, Spain
- Hospital Universitario Son Espases, Palma de Mallorca, Spain
- Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
- Hospital Universitario Virgen Macarena, Seville, Spain
- Hospital de Terrassa, Terrassa, Spain
- Hospital General Universitario de Valencia, Valencia, Spain
- +1 more locations on ClinicalTrials.gov
Collaborators
Spanish Society of Digestive Endoscopy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06462352 on ClinicalTrials.govOther trials for NLRP3-associated autoinflammatory disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07540338A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I DisorderAlzamend Neuro, Inc.
- RECRUITINGPHASE3NCT07343778A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver CirrhosisBeijing Continent Pharmaceutical Co, Ltd.
- RECRUITINGPHASE2NCT07364448A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver FibrosisBeijing Continent Pharmaceutical Co, Ltd.
- RECRUITINGNANCT06544018Circadian Rhythm Deregulation in Patients With CAPSHospices Civils de Lyon
- RECRUITINGNANCT07203963Additional Effects of Niel-asher Technique on Patients With Adhesive CapsulitisRiphah International University
- RECRUITINGPHASE1NCT07532135Safety of Mulberry Leaf Extract Capsule on Blood Glucose Control in Healthy VolunteerChulalongkorn University
- RECRUITINGPHASE4NCT07114120Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan GranulesSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE3NCT06930794A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-PositiveBeijing Pearl Biotechnology Limited Liability Company
See all trials for NLRP3-associated autoinflammatory disease →